These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

102 related articles for article (PubMed ID: 13678396)

  • 41. Electrocardiographic events and cholesterol reduction with pravastatin in patients with hypercholesterolemia: the Hokuriku Lipid Coronary Heart Disease Study-Pravastatin Atherosclerosis Trial.
    Shimizu M; Koizumi J; Miyamoto S; Origasa H; Mabuchi H;
    Int J Cardiol; 2005 Mar; 99(3):395-401. PubMed ID: 15771919
    [TBL] [Abstract][Full Text] [Related]  

  • 42. [New statin introduction. With more power against hypercholesterolemia].
    MMW Fortschr Med; 2002 Dec; 144(50):64. PubMed ID: 14610873
    [No Abstract]   [Full Text] [Related]  

  • 43. Making sense of ENHANCE: ezetimibe (Zetia) lowers LDL cholesterol but doesn't decrease carotid intima-media thickness.
    Smith D
    Mt Sinai J Med; 2008; 75(2):143-7. PubMed ID: 18500716
    [No Abstract]   [Full Text] [Related]  

  • 44. [Dual lipid control without anti-atherosclerosis effect].
    Einecke D
    MMW Fortschr Med; 2008 Apr; 150(16):18, 20. PubMed ID: 18557109
    [No Abstract]   [Full Text] [Related]  

  • 45. Efficacy and safety of ezetimibe added on to atorvastatin (20 mg) versus uptitration of atorvastatin (to 40 mg) in hypercholesterolemic patients at moderately high risk for coronary heart disease.
    Conard SE; Bays HE; Leiter LA; Bird SR; Rubino J; Lowe RS; Tomassini JE; Tershakovec AM
    Am J Cardiol; 2008 Dec; 102(11):1489-94. PubMed ID: 19026302
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Updated guidelines support even lower cholesterol levels for at-risk patients.
    Levenson D
    Rep Med Guidel Outcomes Res; 2004 Aug; 15(15):1, 6-7. PubMed ID: 15320342
    [No Abstract]   [Full Text] [Related]  

  • 47. Optimal lipids, statins, and dementia.
    Lavie CJ; Milani RV
    J Am Coll Cardiol; 2005 Mar; 45(6):963-4; author reply 964-5. PubMed ID: 15766838
    [No Abstract]   [Full Text] [Related]  

  • 48. Primary and secondary prevention of coronary heart disease. Evidence offers multiple strategies.
    Lynn MM
    Adv Nurse Pract; 2000 Jun; 8(6):36-41; quiz 42-3. PubMed ID: 15658206
    [No Abstract]   [Full Text] [Related]  

  • 49. Efficacy and safety of ezetimibe added on to atorvastatin (40 mg) compared with uptitration of atorvastatin (to 80 mg) in hypercholesterolemic patients at high risk of coronary heart disease.
    Leiter LA; Bays H; Conard S; Bird S; Rubino J; Hanson ME; Tomassini JE; Tershakovec AM
    Am J Cardiol; 2008 Dec; 102(11):1495-501. PubMed ID: 19026303
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Cholesterol and your health.
    Korman L
    Lippincotts Prim Care Pract; 1999; 3(3):271-4. PubMed ID: 10711128
    [No Abstract]   [Full Text] [Related]  

  • 51. Low-density lipoprotein cholesterol (LDL-C) levels and LDL-C goal attainment among elderly patients treated with rosuvastatin compared with other statins in routine clinical practice.
    Harley CR; Gandhi S; Blasetto J; Heien H; Sasane R; Nelson SP
    Am J Geriatr Pharmacother; 2007 Sep; 5(3):185-94. PubMed ID: 17996658
    [TBL] [Abstract][Full Text] [Related]  

  • 52. [Critical evaluation of indications for lipid reduction. Cholesterol value updated--risk counts (interview by Dr. Kirsten Westphal)].
    Motz W
    MMW Fortschr Med; 2003 Oct; 145(41):48. PubMed ID: 14655487
    [No Abstract]   [Full Text] [Related]  

  • 53. [Safety and tolerability of nicotinic acid. Results of the multicenter, open, prospective NAUTILUS study].
    Vogt A; Kassner U; Hostalek U; Peiter A; Steinhagen-Thiessen E
    MMW Fortschr Med; 2006 May; 148(18):41. PubMed ID: 16736688
    [No Abstract]   [Full Text] [Related]  

  • 54. Reduction in estimated risk for coronary artery disease after use of ezetimibe with a statin.
    Sampalis JS; Bissonnette S; Habib R; Boukas S;
    Ann Pharmacother; 2007 Sep; 41(9):1345-51. PubMed ID: 17666579
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Optimal low-density lipoprotein is 50 to 70 mg/dl: lower is better and physiologically normal.
    O'Keefe JH; Cordain L; Harris WH; Moe RM; Vogel R
    J Am Coll Cardiol; 2004 Jun; 43(11):2142-6. PubMed ID: 15172426
    [TBL] [Abstract][Full Text] [Related]  

  • 56. [Consequences of the "A to Z" studies: Cholesterol in acute coronary syndrome early and aggressive reduction?].
    März W
    Herz; 2005 Feb; 30(1):78-80. PubMed ID: 16167397
    [No Abstract]   [Full Text] [Related]  

  • 57. Cholesterol lowering drugs.
    N Z Med J; 1990 Apr; 103(888):189. PubMed ID: 2369454
    [No Abstract]   [Full Text] [Related]  

  • 58. National Cholesterol Education Program Adult Treatment Panel-III guidelines and the abolition of symptomatic coronary artery disease.
    Robert Silverstein H
    Am J Cardiol; 2003 Mar; 91(5):654. PubMed ID: 12615289
    [No Abstract]   [Full Text] [Related]  

  • 59. The new cholesterol guidelines: 10 take home messages.
    Harv Heart Lett; 2001 Aug; 11(12):1-5. PubMed ID: 11546613
    [No Abstract]   [Full Text] [Related]  

  • 60. [Who is to be treated with statin?].
    Heebøll-Nielsen NC
    Ugeskr Laeger; 2003 Jun; 165(26):2669-70; author reply 2670. PubMed ID: 12886553
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.